Metastatic Triple-Negative Breast Cancer: Unmet Needs and Future Directions in Care
Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.
Interpreting Data From ASCENT: Practical Use of Sacituzumab Govitecan in mTNBC
Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.
Sacituzumab Govitecan in mTNBC: Results From the ASCENT Study
Metastatic Triple-Negative Breast Cancer: An Evolving Treatment Landscape
Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.